Inhibitors of tumor necrosis factor: New treatment options for rheumatoid arthritis

Cleveland Clinic Journal of Medicine

Volumn 66, Issue 6, 1999, Pages 367-373

  Moreland, Larry W ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; INFLIXIMAB; METHOTREXATE; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG;

BINDING SITE; DRUG APPROVAL; DRUG EFFECT; EDEMA; ERYTHEMA; HUMAN; INFECTION; INJECTION SITE; MEMBRANE BINDING; PAIN; PRURITUS; REVIEW; RHEUMATOID ARTHRITIS; RISK BENEFIT ANALYSIS;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0033023934     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.66.6.367     Document Type: Article

References (13)

1. Cash JM, Klippel JH. Second-line drug therapy for rheumatoid arthritis. N Engl J Med 1994; 330:1368-1375.
2. Ahmadzadeb N, Shingu M, Nobunaga M. The effect of recombinant tumor necrosis factor-alpha on superoxide and metalloproteinase production by synovial cells and chondrocytes. Clin Exp Rheumatol 1990; 8:387-391.
3. MacNaul KL, Chartrain N, Lark M, et al. Differential effects of IL-1 and TNF alpha on the expression of stromelysin, collagenase and the natural inhibitor, TIMP, in rheumatoid synovial fibroblasts. Matrix 1992; 1(Suppl):198-199.
4. Moser RB, Schleiffenbaum B, Groscurth P, et al. Interleukin 1 and tumor necrosis factor stimulate human vascular endothelial cells to promote transendothelial neutrophil passage. J Clin Invest 1989; 83:444-455.
5. Shingu M, Nagai Y, Isayama T, et al. The effects of cytokines on metalloproteinase inhibitors (TIMP) and collagenase production by human chondrocytes and TIMP production by synovial cells and endothelial cells. Clin Exp Immunol 1993; 94:145-149.
6. Brennan FM, Feldmann M. Cytokines in autoimmunity. Curr Opin Immunol 1992; 4:754-759.
7. Chu CQ, Field M, Feldmann M, et al. Localization of tumor necrosis factor a in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis. Arthritis Rheum 1991; 34:1125-1132.
8. Seckinger P, Zhang J, Hauptmann B, et al. Characterization of a tumor necrosis factor a (TNF-α) inhibitor: evidence of immunological cross-reactivity with the TNF receptor. Proc Natl Acad Sci USA 1990; 87:5188-5192.
9. Beutler B, van Huffel C. Unraveling function in the TNF ligand and receptor families. Science 1994; 262:667-668.
10. Banner DW, D'Arcy A, Janes W, et al. Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation. Cell 1993; 73:431-445.
11. Engelmann H, Aderka, Rubinstein M, et al. A tumor necrosis factor binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J Biol Chem 1989; 264:11974-11980.
12. Olsson I, Lantz M, Nilsson E, et al. Isolation and characterization of a tumor necrosis factor binding protein from urine. Eur J Haematol 1989; 42:270-275.
13. Cope AP, Aderka D, Doherty M, et al. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum 1992; 35:1160-1169.